GlaxoSmithKline Consumer Healthcare Ltd reported a net profit of ₹221.06 crore for the quarter ended December 31, up 35.07 per cent as against ₹163.66 crore in the corresponding quarter the previous fiscal.
Revenue from operations grew 7.45 per cent to ₹1,116.82 crore in the quarter under review.
In a statement, Navneet Saluja, Managing Director, GlaxoSmithKline Consumer Healthcare Ltd, said: “We have been witnessing healthy sustainable growth in our financial performance in the past few quarters. This growth is reflective of the unflinching trust that our consumers have in our products.”
Meanwhile, the company said that its proposed merger deal with Hindustan Unilever Ltd (HUL) was approved by the Competition Commission of India on January 23. “The merger is now subject to the receipt of other necessary statutory and regulatory approvals under applicable laws. The merger process is moving along expected timelines,” it added.
On December 3, GlaxoSmithKline had announced the divestments of Horlicks and other consumer healthcare nutrition brands to Unilever Plc, as well as the merger of GlaxoSmithKline Consumer Healthcare Ltd with HUL.